The aim of this study is to correlate radiological CT imaging approaches to the lesion and pathology results in lung lesions. In this study, lung biopsy pathology results of 54 cases sent to the pathology department between 2020-2023 were compared with existing radiological CT images. The cases were grouped pathologically as benign and malignant, and the malignant cases were classified according to their tumor types. Radiologically, the cases were divided into groups as benign or malignant, peripheral or centrally located. In this study, core biopsies of a total of 54 cases, 15 female (27.7%) and 39 (72.3%) male, were evaluated. The average age of the patients was found to be 61.1 (21-95). Of a total of 54 lung solid mass lesions, 38 (70.4%) were peripheral and 16 (29.6%) were centrally located. In the radiological double-blind evaluation, 29 (53.7%) of the cases were diagnosed as malignant, while 24 (44.4%) were pathologically diagnosed as malignant. While squamous cell carcinoma (SCC), the most common pathologically malignant tumor, was seen in 9 cases, the second most common small cell carcinoma (SCLC) was detected in 7 cases. In conclusion, pathology and radiological imaging in lung lesions are important in early diagnosis, effective treatment and prolonged survival, and correctly performed radiological imaging and histopathological correlation with biopsy with today's interventional techniques in early suspicious cases have an important place in reducing morbidity and mortality.
This study received approval from the local ethics committee of our institution (Decision no:2023/12-07).
No financial support or funding was received for this paper.
Primary Language | English |
---|---|
Subjects | Pathology, Radiology and Organ Imaging |
Journal Section | Research Article |
Authors | |
Publication Date | March 28, 2025 |
Submission Date | July 25, 2024 |
Acceptance Date | March 17, 2025 |
Published in Issue | Year 2025 Volume: 42 Issue: 1 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.